J. Christopher Naftzger
CIK 1496194 · General Counsel and CCO · last filed 2025-02-19
J. Christopher Naftzger is a General Counsel and CCO who has filed 16 SEC Form 4 insider transactions across 3 companies since 2010. The most recent filing, for ABUS, was dated Feb 19, 2025. Across all open-market trades the lifetime net is −$11.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $593.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ABUS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LEWISBERRY, PA 17339
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABUS | General Counsel and CCO | 140,544 | $4.22 | $593.1K | -$37.2K | 4 | 2025-02-19 |
| Nabriva Therapeutics plc (NBRV) Delisted | General Counsel and Corp Sec | 280 | $1.42 | $398 | $4.1K | 4 | 2022-08-15 |
| Unilife Corp (UNIS) Delisted | See Remarks | 22,444 | — | — | $22.0K | 7 | 2013-05-30 |
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-19 | ABUS | Grant (A) | +54,300 | $0 | EDGAR |
| 2025-02-05 | ABUS | Sell (S) | −11,333 | -$37.2K | EDGAR |
| 2025-02-04 | ABUS | Notice (144) | −11,333 | -$37.2K | EDGAR |
| 2024-02-05 | ABUS | Grant (A) | +95,100 | $0 | EDGAR |
| 2023-07-12 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2022-08-15 | Nabriva Therapeutics plc (NBRV) Delisted | Exer (M) | — | $0 | EDGAR |
| 2022-02-01 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-28 | Nabriva Therapeutics plc (NBRV) Delisted | Buy (P) | +7,000 | $4.1K | EDGAR |
| 2021-10-01 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-30 | Unilife Corp (UNIS) Delisted | Grant (A) | +165,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.